Gonadotrpin ovarian stimulation Aboubakr elnashar

1. Gonadotrpin ovarian
stimulation
Aboubakr elnashar
Benha university Hospital, EgyptAboubakr Elnashar

2. Contents
Types of anovulation
Types of ovarian stimulations
Types of Gnt
Patient selection
Indications
Contraindications
Protocols
Monitoring
Results
Complications
Conclusion
Aboubakr Elnashar

3. Anovulation
% Type Hormonal profile
5-10%
WHO type I
(Hypogonadotropic
Hypoestrogenic)
E2
FSH
75-80%
WHO type II
Normogenadotrophic
Normoestrogenic
Normal E2
Normal FSH
10-20%
WHO type III
(Hypergonadotropic
Hypoestrogenic)
E2
FSH
5-10%
WHO type IV
(Hyperprolactinemia) prolactin
WHO Scientific group, Geneva 1976, Report 514, Rowe et al, 1993
Aboubakr Elnashar

4. Types of ovarian stimulation
Controlled
ovarian
stimulation
Super
ovulation
Induction of
ovulation
Anovulatory or ovulatoryAnovulatoryPatient
Multiple> oneOne mature
follicle
Objective
IVFIUI
Unexp inf
Example
Down regulation
Stimulation
Prevent premature
LH surge
StimulationStimulationMethod
Aboubakr Elnashar

5. Gonadotropin Preparations
• 3 main preparations: FSH, LH & HCG
• 2 types
I. Urinary
1. HMG
2. Highly purified HMG
3. Purified FSH
4. Highly purified FSH
5. Urinary HCG
II. Recombinant
1. Rec FSH
2. Rec HCG
3. Rec LH
Aboubakr Elnashar

6. Aboubakr Elnashar

7. Aboubakr Elnashar

8. Aboubakr Elnashar

9. Preparation Trade name Route U.pr FSH LH Price Company
HMG Pergonal,
Humegon,
Menogon,
Merional
IM 95% 75 75 Serono
Organon
Ibsa
H.P.HMG Menopur SC <5% 75 75 Ferring
Purified
FSH
Metrodine IM <5% 75
Urofillotropin
<0.1 Serono
H.P.FSH Fostimon
Metrodine HP
Bravelle
SC,
IM
<5% 75
Urofillotropin
<0.001 Ibsa
Serono
Ferring
HCG Pregnyl
Profasi
IM 95% Organon
Serono
H.P.HCG Choriomon SC,
IM
<5% Ibsa
I. Urinary Gonadotropins
Aboubakr Elnashar

10. II. Recombinant Gonadotropins
Preparation Trade name Route U.pr FSH LH company Price
1. FSH Gonal-f (follitropin)
Gonal-f FbM Pen
Puregon (follitropin)
Puregon pen
SC, IM
SC, IM
SC,IM
SC, Im
-
-
-
-
75,150
300,450,900
50,100
300,600
-
-
-
-
Serono
Serono
MSD
MSD
145
1200
180
--------
2. HCG Ovitrelle
Choriogonadotropin
SC - Serono
3. LH Luveris
lutotropin
SC - Serono
Aboubakr Elnashar

11. Patient selection
I. Basic investigations of infertility
1. Semen analysis
2. HSG
3. Midluteal P
II. If amenorrhea &/or galactorrhea:
Workup
Aboubakr Elnashar

12. Indications
I. Induction of ovulation
1. Hypogonadotropic Hypogonadism
(hypothalamic amenorrhea, WHO Group I)
Gnt secretion:
extremely low
HMG:
only effective Gnt {contains both FSH and LH}.
LH-containg Gnt if LH <3 IU/L (Speroff, 2009)
CC& related medications:
ineffective {their actions require an intact& functional
hypothalamic-pituitary-ovarian axis}.
Aboubakr Elnashar

13. 2. CC resistance or failure
Resistance (No ovulation) or
Failure (No pregnancy)
PCOS(WHO Group II)
Gnt: normal
LH: may be high
Aboubakr Elnashar

14. Clomiphene Citrate Resistantce
Incidence:
20%
Define
No ovulation after treatment with CC,
{100 mg, for 5 days in 3 cycles} (Coelingh
Bennink, 1998).
Causes:
Hyperandrogenic
Obese
Severe insulin resistance
(Murakawa et al.,1999; Speroff et al., 1999).
Aboubakr Elnashar

15. Clomiphene citrate failure:
Define:
No pregnancy despite of ovulation with CC
Causes:
long half-life& peripheral anti-estrogenic effects on
endometrium& cervical mucus.
low fertilization rate
variable implantation rate
deficient corpus luteum function (Speroff et al., 2005)
Aboubakr Elnashar

16. Dosage:
Minimum: single dominant follicle.
{Response can vary greatly from individual to
individual& from cycle to cycle}
Monitoring:
Adjust dosage
Timing of ovulation.
Aboubakr Elnashar

17. Luteal-phase support
seldom necessary
{endogenous LH levels typically are more than
sufficient to support normal luteal function}.
Indication
1. GnRHa used
2. Evidence of poor luteal function after otherwise
successful ovulation induction
 How:
progesterone
{higher risk of OHSS associated with hCG}
Aboubakr Elnashar

18. II. Superovulation
1. Unexplained Infertility
Aim:
increase cycle fecundity
Aboubakr Elnashar

19. 2. IUI
Most effective when combined with IUI
PR/cycle: 17 %
Aboubakr Elnashar

20. Monitoring:
{avoid obviously excessive stimulation}.
Risks
Multiple pregnancy: > in clomiphene-resistant anovulatory
women
Luteal support:
Not required {combined contributions of two or more corpora
lutea may be reliably expected to yield supraphysiologic luteal-
phase serum progesterone concentrations}
Aboubakr Elnashar

21. III. COS
IVF or ICSI
Aim:
induce multifollicular growth.
maintaining a subthreshold level of Gnt during the
time of follicular recruitment: overriding the process of
selection of a single dominant follicle.
How:
GnRHa, or antagonist to block endogenous LH
production& LH surges.
Gnt
HCG
When an appropriate follicular size is observed: final
maturation of the follicles Aboubakr Elnashar

22. Contraindications
Rare:
1. Hypersensitivity to Gnt or to any of
the excipients.
2. Ovarian, uterine, or breast cancers.
3. Tumors of the hypothalamus&
pituitary gland
4. Ovarian enlargement or cyst not
due to PCOS
5. Pregnancy& lactation.
6. Gynecological hemorrhages of
unknown origin.
Aboubakr Elnashar

23. Aboubakr Elnashar

24. Aboubakr Elnashar

25. The starting dose of Gnt
Depend on:
1. The intended goal:
unifollicular ovulation or superovulation
2. Age
3. BMI
4. PCOS
5. Ovarian reserve: baseline FSH, ACF, AMH
6. Previous response.
Aboubakr Elnashar

26. Life cycle of ovarian follicles
Aboubakr Elnashar

27. Aboubakr Elnashar

28. High
response
Low
response
164Total AFC
40.5AMH ng/ml
410FSH IU/L
Aboubakr Elnashar

29. Aboubakr Elnashar

30. Aboubakr Elnashar

31. Protocols
I. Step-up:
1. Conventional=Standard
2. Low dose
3. Chronic low dose
II. Step-down
III. Step-up, step-down
Aboubakr Elnashar

32. I. Step up
Principle:
Stepwise increase in FSH {determine the FSH threshold
for follicular development}
Aboubakr Elnashar

33. 1. Conventional:
Starting dose: 150 IU/d:
Duration of starting dose: 5 d
Increased by: 75 IU/3-5 d
Excessive follicle development
Increased OHSS
(Thompson and Hansen, 1970; Dor et al., 1980; Wang and Gemzell, 1980).
No longer recommended
(Buvat et al., 1989; Brzyski et al., 1995)
Aboubakr Elnashar

34. Starting dose: 150 IU/d
2 FSH/hMG/day
Day 3Day 3 Day 7Day 75 days5 days
If
Follicle > 12 mm
E2 > 400U
Continue
2 FSH/d
No response® 3 FSH/day
for 3 more days
Endocrine Rev. 1997; 18: 71
Aboubakr Elnashar

35. 2. low-dose
•Stating dose: 75 IU/d
(White et al., 1996; Hayden et al., 1999; Balasch et al., 2000; Calaf et
al., 2003).
•Duration of starting dose: 5-7 d
-No follicle development: increase the dose by
100%
-Follicle growth: maintain same dose until
follicular selection is achieved.
-Mono-ovulation: 69%
- MP: 5.7%
- OHSS: 0.14%
(Homburg & Howles, 1999. Hum. Reprod. Update 5:493-499).
Aboubakr Elnashar

36. Starting dose:75 IU/d
If
mm12>Follicle
E2 > 400
Continue
1 FSH/d
No response 150 FSH/d
for 1 more w (max. 3 amp.)
Endocrine Rev. 1997; 18: 71
75 FSH/hMG/day
Day 3 Day 75 days
Aboubakr Elnashar

37. Low doseConventional
≤6%36%Multiple pregnancy
≤1%6%OHSS
Aboubakr Elnashar

38. 3. Chronic low-dose
•Starting dose: 37.5-75 IU
•Duration of starting dose:14 d
•The weekly dose increment: reduced from 100% to 50% or
37.5 IU
(Seibel et al., 1984; Polson et al., 1987; Sagle et al., 1991; Dale et al., 1993).
:Markedly ↓excessive ov stimulation
Marked ↓OHSS.
Aboubakr Elnashar

39. 0 14 21 28 35
75 iu
112.5 iu
150 iu
187.5 iu
225 iu
Days
7
37.5 iu
½ Amp.
One Amp.
42 49
2 Amp.
3 Amp.
White et al. J Clin Endocrinol Metab 1996;81:3821–4
Aboubakr Elnashar

40. Monitoring in superovulation
1- TVS:
Baseline D2 or 3 of the cycle
 ovarian cyst:
> 30 mm: decreased fecundity (Akin and Shepard, 1993).
: postpone Gnt.
AFC:
Aboubakr Elnashar

41. Serial
D5-7 of stimulation
Repeat /2-3 d depending on the size of
leading follicle, until it is 18 mm
a. Follicles:
number & size
Documentation of all follicles >10 mm {predict the risk of
multiple pregnancies}.
1 or 2 follicles 18-20 mm: HCG
Daily SI on the day of HCG& for the next 2 days
Aboubakr Elnashar

42.  > 3 follicles > 16 mm:
(Macklon et al, 1999).
>4 follicles ≥ 14 mm
(Kamrava et al., 1982; Hugues et al., 2006).
Stop stimulation& hCG withheld
 Gnt follicles mature at 15-18 mm
CC follicles mature at 18-20 mm
(Sperof,f 2005)
Aboubakr Elnashar

43. Aboubakr Elnashar

44. b. Endometrial thickness:
<6 mm: No pregnancies
9-10 mm or more: The chance of pregnancy is
great
(Isaacs et al, 1996).
Aboubakr Elnashar

45. 2-E2 peak (pg/ml):
<200
pregnancies are rare
500-1500
optimal
1500-2000
risk of OHSS is significant
>2000 pg./ml:
hCG is not given
Cyle is cancelled
(Speroff et al, 2006). Aboubakr Elnashar

46. Results
I. Ovulation
>90%
Aboubakr Elnashar

47. II. Pregnancy
Low:
1. hyperandrogenic chronic anovulation group
2. Above 35 y
CC resistant
anovulatory
Hypogonadotropic
hypogonadism
5-15%25%Cycle fecundity
30-60%90%Cumulative PR after up to 6 cycles
Aboubakr Elnashar

48. III. Miscarriage
20-25%
moderately higher than is generally (15%).
1. advanced maternal age
2. obesity
Low in
hypogonadotropic hypogonadism
Higher in
clomiphene-resistant anovulatory women
Aboubakr Elnashar

49. IV. Congenital anomalies.
No increase
Aboubakr Elnashar

50. Complications
I. Multiple pregnancy:
Low dose protocol: <6%
Conventional dose protocol: 36%
II. OHSS
Low dose protocol: <1%
Conventional dose protocol: 4.6%
III. Breast and Ovarian Cancer: No increase
IV. Local allergic reactions.
Aboubakr Elnashar

51. Conclusion
The intended goal: unifollicular ovulation or
superovulation
 3 main preparations: FSH, LH & HCG & 2
types
 Basic investigations of infertility
 Indications are hypogonadotropic
hypogonadism, CC failure or resistance,
unexplained infertility, IUI
Aboubakr Elnashar

52.  Contraindications are rare
 Step up chronic low dose protocol is
recommended in PCOS
 US monitoring is mandatory
 Ovulation 90%, Pregnancy 30-90%,
miscarriage 20%
 Complications are OHSS &multiple
pregnancy
Aboubakr Elnashar

53. Thank you
Face book
Aboubakr Elnashar Lectures
Aboubakr Elnashar